Compare MESO & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MESO | NUV |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2005 | N/A |
| Metric | MESO | NUV |
|---|---|---|
| Price | $16.47 | $8.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 180.2K | ★ 445.8K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | N/A |
| Revenue Next Year | $30.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.05 | $8.82 |
| 52 Week High | $21.50 | $9.26 |
| Indicator | MESO | NUV |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 32.87 |
| Support Level | $15.37 | $8.82 |
| Resistance Level | $17.10 | $9.15 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 1.06 | 11.91 |
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.